Successful donor engraftment and repair of the blood-brain barrier in cerebral adrenoleukodystrophy

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Adrenoleukodystrophy (ALD) is caused by mutations within the X-linked ABCD1 gene, resulting in the inability to transport acylated very long chain fatty acids (VLCFAs) into the peroxisome for degradation. VLCFAs subsequently accumulate in tissues, including the central nervous system. Up to 40% of boys develop a severe progressive demyelinating form of ALD, cerebral ALD, resulting in regions of demyelination observed on brain magnetic resonance imaging that are associated with a “garland ring” of gadolinium contrast enhancement. Gadolinium enhancement indicates blood-brain barrier (BBB) disruption and an active inflammatory disease process. Only hematopoietic cell transplant (HCT) has been shown to halt neurologic progression, although the mechanism of disease arrest is unknown. We evaluated imaging- and transplant-related biomarkers in 66 males who underwent HCT. In 77% of patients, gadolinium contrast resolved by 60 days post-HCT. We determined that time to neutrophil recovery and extent of donor chimerism correlated significantly with time to contrast resolution post-HCT. Graft failure was associated with a significantly slower rate of contrast resolution (P < .0001). Time to neutrophil recovery remained significant in multivariate analysis with other biomarkers (P 5 .03). Our data suggest that robust donor myeloid recovery is necessary for timely repair of the BBB.

Original languageEnglish (US)
Pages (from-to)1378-1381
Number of pages4
JournalBlood
Volume133
Issue number12
DOIs
StatePublished - Mar 21 2019

Fingerprint

Adrenoleukodystrophy
Transplants
Blood-Brain Barrier
Repair
Tissue Donors
Gadolinium
Biomarkers
Recovery
Fatty Acids
Neutrophils
Imaging techniques
Neurology
Magnetic resonance
X-Linked Genes
Chimerism
Peroxisomes
Grafts
Demyelinating Diseases
Brain
Nervous System

Cite this

@article{5cfe9eeda1204893bd9e704cda756e6d,
title = "Successful donor engraftment and repair of the blood-brain barrier in cerebral adrenoleukodystrophy",
abstract = "Adrenoleukodystrophy (ALD) is caused by mutations within the X-linked ABCD1 gene, resulting in the inability to transport acylated very long chain fatty acids (VLCFAs) into the peroxisome for degradation. VLCFAs subsequently accumulate in tissues, including the central nervous system. Up to 40{\%} of boys develop a severe progressive demyelinating form of ALD, cerebral ALD, resulting in regions of demyelination observed on brain magnetic resonance imaging that are associated with a “garland ring” of gadolinium contrast enhancement. Gadolinium enhancement indicates blood-brain barrier (BBB) disruption and an active inflammatory disease process. Only hematopoietic cell transplant (HCT) has been shown to halt neurologic progression, although the mechanism of disease arrest is unknown. We evaluated imaging- and transplant-related biomarkers in 66 males who underwent HCT. In 77{\%} of patients, gadolinium contrast resolved by 60 days post-HCT. We determined that time to neutrophil recovery and extent of donor chimerism correlated significantly with time to contrast resolution post-HCT. Graft failure was associated with a significantly slower rate of contrast resolution (P < .0001). Time to neutrophil recovery remained significant in multivariate analysis with other biomarkers (P 5 .03). Our data suggest that robust donor myeloid recovery is necessary for timely repair of the BBB.",
author = "Orchard, {Paul J} and Nascene, {David R} and Miller, {Weston P} and Gupta, {Ashish O} and Kenney-Jung, {Daniel L} and Lund, {Troy C}",
year = "2019",
month = "3",
day = "21",
doi = "10.1182/blood-2018-11-887240",
language = "English (US)",
volume = "133",
pages = "1378--1381",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "12",

}

TY - JOUR

T1 - Successful donor engraftment and repair of the blood-brain barrier in cerebral adrenoleukodystrophy

AU - Orchard, Paul J

AU - Nascene, David R

AU - Miller, Weston P

AU - Gupta, Ashish O

AU - Kenney-Jung, Daniel L

AU - Lund, Troy C

PY - 2019/3/21

Y1 - 2019/3/21

N2 - Adrenoleukodystrophy (ALD) is caused by mutations within the X-linked ABCD1 gene, resulting in the inability to transport acylated very long chain fatty acids (VLCFAs) into the peroxisome for degradation. VLCFAs subsequently accumulate in tissues, including the central nervous system. Up to 40% of boys develop a severe progressive demyelinating form of ALD, cerebral ALD, resulting in regions of demyelination observed on brain magnetic resonance imaging that are associated with a “garland ring” of gadolinium contrast enhancement. Gadolinium enhancement indicates blood-brain barrier (BBB) disruption and an active inflammatory disease process. Only hematopoietic cell transplant (HCT) has been shown to halt neurologic progression, although the mechanism of disease arrest is unknown. We evaluated imaging- and transplant-related biomarkers in 66 males who underwent HCT. In 77% of patients, gadolinium contrast resolved by 60 days post-HCT. We determined that time to neutrophil recovery and extent of donor chimerism correlated significantly with time to contrast resolution post-HCT. Graft failure was associated with a significantly slower rate of contrast resolution (P < .0001). Time to neutrophil recovery remained significant in multivariate analysis with other biomarkers (P 5 .03). Our data suggest that robust donor myeloid recovery is necessary for timely repair of the BBB.

AB - Adrenoleukodystrophy (ALD) is caused by mutations within the X-linked ABCD1 gene, resulting in the inability to transport acylated very long chain fatty acids (VLCFAs) into the peroxisome for degradation. VLCFAs subsequently accumulate in tissues, including the central nervous system. Up to 40% of boys develop a severe progressive demyelinating form of ALD, cerebral ALD, resulting in regions of demyelination observed on brain magnetic resonance imaging that are associated with a “garland ring” of gadolinium contrast enhancement. Gadolinium enhancement indicates blood-brain barrier (BBB) disruption and an active inflammatory disease process. Only hematopoietic cell transplant (HCT) has been shown to halt neurologic progression, although the mechanism of disease arrest is unknown. We evaluated imaging- and transplant-related biomarkers in 66 males who underwent HCT. In 77% of patients, gadolinium contrast resolved by 60 days post-HCT. We determined that time to neutrophil recovery and extent of donor chimerism correlated significantly with time to contrast resolution post-HCT. Graft failure was associated with a significantly slower rate of contrast resolution (P < .0001). Time to neutrophil recovery remained significant in multivariate analysis with other biomarkers (P 5 .03). Our data suggest that robust donor myeloid recovery is necessary for timely repair of the BBB.

UR - http://www.scopus.com/inward/record.url?scp=85063646604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063646604&partnerID=8YFLogxK

U2 - 10.1182/blood-2018-11-887240

DO - 10.1182/blood-2018-11-887240

M3 - Article

C2 - 30635285

AN - SCOPUS:85063646604

VL - 133

SP - 1378

EP - 1381

JO - Blood

JF - Blood

SN - 0006-4971

IS - 12

ER -